Introduction The beneficial effects of glucagon-like peptide 1 (GLP-1) and its related substances such as inhibitors of dipeptidyl peptidase IV, its degrading enzyme, on the pancreatic β-cells have been reported; these agents enhance
Search Results
Shin Tsunekawa, Naoki Yamamoto, Katsura Tsukamoto, Yuji Itoh, Yukiko Kaneko, Toshihide Kimura, Yoh Ariyoshi, Yoshitaka Miura, Yutaka Oiso and Ichiro Niki
João Paulo G Camporez, Mohamed Asrih, Dongyan Zhang, Mario Kahn, Varman T Samuel, Michael J Jurczak and François R Jornayvaz
., Yellow Springs, OH, USA). Plasma fatty acids were determined with the NEFA C Kit (Wako Pure Chemical Industries, Osaka, Japan). Plasma insulin, glucagon, and adiponectin were measured by RIA Kits (Millipore, Billerica, MA, USA). For glucagon measurements
E N Fazio, M Everest, R Colman, R Wang and C L Pin
.1% Triton X-100) then incubated for 1 h with primary antibodies, including rabbit anti-amylase (1:1000; Calbiochem), mouse anti-insulin (1:500; Sigma), rabbit anti-glucagon (1:100; Sigma), rabbit anti-pdx1 (1:1000; a generous gift from Dr C. Wright
Berit Svendsen, Ramona Pais, Maja S Engelstoft, Nikolay B Milev, Paul Richards, Charlotte B Christiansen, Kristoffer L Egerod, Signe M Jensen, Abdella M Habib, Fiona M Gribble, Thue W Schwartz, Frank Reimann and Jens J Holst
Introduction The incretin hormones, glucagon-like peptide-1 (GLP1) and glucose-dependent insulinotropic polypeptide (GIP) strongly potentiate postprandial insulin secretion and are therefore important regulators of glucose homeostasis. They are
C Y Shan, J H Yang, Y Kong, X Y Wang, M Y Zheng, Y G Xu, Y Wang, H Z Ren, B C Chang and L M Chen
to affect host metabolism and energy storage ( Ley et al . 2006 ) and to affect gut permeability and, as a consequence, give rise to metabolic endotoxemia and higher plasma lipopolysaccharide (LPS). In addition, gut peptides such as glucagon
Akiko Mizokami, Satoru Mukai, Jing Gao, Tomoyo Kawakubo-Yasukochi, Takahito Otani, Hiroshi Takeuchi, Eijiro Jimi and Masato Hirata
et al. 2014 ) or indirectly through stimulation of the secretion of glucagon-like peptide-1 (GLP-1) from intestinal endocrine cells ( Mizokami et al. 2013 , 2014 ). GLP-1 is a member of the incretin family of hormones that are secreted from
Srilaxmi Kalavalapalli, Fernando Bril, Joy Guingab, Ariana Vergara, Timothy J Garrett, Nishanth E Sunny and Kenneth Cusi
under investigation for NASH, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown a significant promise for the treatment of NAFLD ( Ding et al. 2006 , Blonde & Russell-Jones 2009 , Cusi 2012 , Armstrong et al. 2013 , 2016 a , b
Helena A Walz, Linda Härndahl, Nils Wierup, Emilia Zmuda-Trzebiatowska, Fredrik Svennelid, Vincent C Manganiello, Thorkil Ploug, Frank Sundler, Eva Degerman, Bo Ahrén and Lena Stenson Holst
Introduction Intracellular cAMP is crucial for pancreatic β-cell function. Insulin secretion stimulated by glucagon and incretin hormones, e.g. glucagon-like peptide-1 (GLP-1), is exerted via increased cAMP ( Gromada et al. 1998
Joëlle Dupont, Sophie Tesseraud, Michel Derouet, Anne Collin, Nicole Rideau, Sabine Crochet, Estelle Godet, Estelle Cailleau-Audouin, Sonia Métayer-Coustard, Michel J Duclos, Christian Gespach, Tom E Porter, Larry A Cogburn and Jean Simon
the fasted state, the control of glycemia is in contrast dependent on glucagon since fasted pancreatectomized chickens tend to develop hypoglycemia rather than hyperglycemia ( Simon 1989 ). Similar conclusions have been obtained in ducks ( Mirsky et
M-J Kim, J-H Kang, Y G Park, G R Ryu, S H Ko, I-K Jeong, K-H Koh, D-J Rhie, S H Yoon, S J Hahn, M-S Kim and Y-H Jo
Introduction Glucagon-like peptide-1 (GLP-1) has been of much interest due to its β-cell-proliferating effect and role as an incretin hormone in synergizing with glucose to enhance insulin release ( Ørskov 1992 , Egan et al. 2003
